针对神经母细胞瘤的生长因子信号传导和克服药物耐药性的进展
Karina Ivanenko1, Ruslan Shaymardanov2, Vladimir Prassolov1
1Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia.
Cells
|January 9, 2026
概括
神经母细胞瘤是一种致命的儿童癌症,通常会过度激活生长因子信号. 受体氨酸激酶 (RTK) 抑制剂表现有前途,但由于瘤细胞多样性而面临阻力,需要组合疗法.
科学领域:
- 儿科瘤学 儿科瘤学
- 发展生物学 发展生物学
- 癌症信号传递 癌症信号传递
背景情况:
- 神经母细胞瘤起源于神经细胞,是儿童癌症死亡的主要原因.
- 增长因子信号传递对于神经顶部发育至关重要,并且在神经母细胞瘤中经常存在失调.
- 受体氨酸激酶 (RTK) 抑制剂提供了有针对性的方法,但耐药性是一个重大挑战.
研究的目的:
- 审查生长因子受体在神经和神经母细胞瘤发育中的作用.
- 系统地概述神经母细胞瘤的RTK抑制剂及其临床状态.
- 探索组合疗法的耐药性机制和策略.
主要方法:
- 对神经和神经母细胞瘤单细胞研究的文献综述.
- 对神经母细胞瘤临床发展中的RTK抑制剂的系统分析.
- 探索内异质性和耐药机制,如上腺素转移到介质酶的转变.
主要成果:
- 增长因子信号通路是神经母细胞瘤的关键驱动因素,提供治疗点.
- 内异质性,特别是上腺到介质酶的转变,有助于对RTK抑制剂的耐药性.
- 目前的RTK抑制剂显示出可变的疗效,往往需要组合策略.
结论:
- 用RTK抑制剂准生长因子受体信号传递是神经母细胞瘤的一个有希望的策略.
- 克服抵抗需要解决瘤细胞的可塑性和逃生机制.
- 组合疗法有可能改善高风险神经母细胞瘤的结果.
相关概念视频
Targeted Cancer Therapies
8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.6K
Mitogens and the Cell Cycle
7.7K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
7.7K
Treatment Resistant Cancers
3.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.7K
Combination Therapies and Personalized Medicine
5.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K


